A review of Judah Folkman's remarkable achievements in biomedicine

Cao, Yihai; Langer, Robert

doi:10.1073/pnas.0806582105

Cited by 53 publications

(89 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Folkman proposed that tumor growth depends on angiogenesis and that blocking of nutrition supply could inhibit or eliminate tumors (Sherwood et al, 1971). According to Folkman and colleagues'study, tumor vasculature is regulated by a defined set of pro-angiogenic and anti-angiogenic factors, and the tumor often expresses and secretes excessive proangiogenic factors and breaks the balance between above mentioned factors, thus turns the "angiogenic switch" towards an angiogenic phenotype, and their ingenious efforts lead to the discovery of vascular endothelial growth factor (VEGF) (Cao et al, 2008). Tumors can engulf existing blood vessels or form new blood vessels, however, the resulted new vessels are often both structurally and functionally abnormally.…”

Section: E G F R S I G N a L P A T H W A Y Tu M O R Microenvironmenmentioning

confidence: 99%

Concomitant EGFR Inhibitors Combined with Radiation for Treatment of Non-small Cell Lung Carcinoma

Zheng¹,

Yu²,

Jia³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

Section: E G F R S I G N a L P A T H W A Y Tu M O R Microenvironmenmentioning

confidence: 99%

Concomitant EGFR Inhibitors Combined with Radiation for Treatment of Non-small Cell Lung Carcinoma

Zheng¹,

Yu²,

Jia³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…Subsequently, migration and proliferation of the endothelial cells ensues, and finally, formation and maturation of blood vessels occur. The first scientist to indicate the potential role of angiogenesis in cancer development was Judah Folkman in 1971 [41]. There are multiple factors with pro-and antiangiogenic properties.…”

Section: Discussionmentioning

confidence: 99%

A rare CD5-positive subgroup of diffuse large B-cell lymphoma – clinical, morphological and immunophenotypic features in Polish patients

Woźnialis¹,

Gierej²,

Popławska³

et al. 2016

pjp

View full text Add to dashboard Cite

The aim of the study was to assess the incidence of CD5-positive diffuse large B-cell lymphoma (DLBCL) in the Polish population and to describe its morphologic and clinical characteristics. The study included 36 patients with CD5-positive DLBCL, diagnosed and treated in the Maria Skłodowska-Curie Institute and Oncology Centre, Warsaw, Poland and the Medical University of Warsaw, Poland in the years 2002-2013. The control group consisted of 28 patients with CD5-negative DLBCL. CD5-positive DLBCL accounted for 6.26% of all DLBCL cases diagnosed in the Maria Skłodowska-Curie Institute and Oncology Centre in the years 2008-2012. The incidence is comparable to other European countries, lower than noted in Japan and higher than in the US. Patients with CD5-positive DLBCL, in comparison to the CD5-negative group, were characterized by: (1) older age (≥ 60 vs. younger) and worse general status (ECOG ≥ 2 vs. < 2), (2) lower frequency of complete remission (CR), (3) higher expression of unfavorable prognostic factors (BCL2, FOXP1, CD44) and MMP-9, and (4) lower expression of CD30, cyclin D1, cyclin D3 and TIMP-2.

show abstract

“…Tumors actively secrete growth factors that trigger angiogenesis. The concept of angiogenesis was established by Prof. Judah Folkman [25]. He proposed that tumor growth depends on angiogenesis and proposed the use of angiogenesis inhibitors as antitumor agents, i.e., to target activated endothelial cells.…”

Section: Anticancer Agentsmentioning

confidence: 99%

Importance of microbial natural products and the need to revitalize their discovery

Demain

2014

Journal of Industrial Microbiology and Biotechnology

369

216

View full text Add to dashboard Cite

Microbes are the leading producers of useful natural products. Natural products from microbes and plants make excellent drugs. Significant portions of the microbial genomes are devoted to production of these useful secondary metabolites. A single microbe can make a number of secondary metabolites, as high as 50 compounds. The most useful products include antibiotics, anticancer agents, immunosuppressants, but products for many other applications, e.g., antivirals, anthelmintics, enzyme inhibitors, nutraceuticals, polymers, surfactants, bioherbicides, and vaccines have been commercialized. Unfortunately, due to the decrease in natural product discovery efforts, drug discovery has decreased in the past 20 years. The reasons include excessive costs for clinical trials, too short a window before the products become generics, difficulty in discovery of antibiotics against resistant organisms, and short treatment times by patients for products such as antibiotics. Despite these difficulties, technology to discover new drugs has advanced, e.g., combinatorial chemistry of natural product scaffolds, discoveries in biodiversity, genome mining, and systems biology. Of great help would be government extension of the time before products become generic.

show abstract

A review of Judah Folkman's remarkable achievements in biomedicine

Cited by 53 publications

References 23 publications

Concomitant EGFR Inhibitors Combined with Radiation for Treatment of Non-small Cell Lung Carcinoma

Concomitant EGFR Inhibitors Combined with Radiation for Treatment of Non-small Cell Lung Carcinoma

A rare CD5-positive subgroup of diffuse large B-cell lymphoma – clinical, morphological and immunophenotypic features in Polish patients

Importance of microbial natural products and the need to revitalize their discovery

Contact Info

Product

Resources

About